Xtant Medical Holdings, Inc. (XTNT)
Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological surgeons both within the United States and globally. Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extremities, and posterolateral spine. Additionally, the line features OsteoFactor, containing diverse proteins and peptides that facilitate bone formation and remodeling, along with OsteoWrap and OsteoVive Plus, a cellular bone matrix enriched with growth factors. 2. Allograft Technologies: Under the 3Demin brand, Xtant Medical provides a range of allografts (human bone grafts) engineered to maximize both osteoconductivity and osteoinductive capabilities. This includes specialized sports allografts used for repairing anterior and posterior cruciate ligaments, ACL reconstruction, and meniscal repairs. They also offer milled spinal allografts, where cortical bone is precisely shaped to specific dimensions, as well as traditional allografts applicable across numerous medical disciplines such such as orthopedics, neurology, podiatry, oral/maxillofacial surgery, genitourinary, and plastic/reconstructive surgery. 3. Spinal Fixation and Fusion Systems: The company furnishes a variety of sophisticated spinal devices. These include the Certex spinal fixation system, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, the Xpress minimally invasive pedicle screw system, and Fortex Pedicle screw systems. Further systems encompass Calix, for use in cervical and thoracolumbar regions, the Axle-X interspinous fusion system, Irix-C for cervical integrated fusion, and the Irix-A Lumbar integrated fusion system. The company underwent a name change in July 2015, transitioning from its former identity as Bacterin International Holdings, Inc. to Xtant Medical Holdings, Inc.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Xtant Medical Holdings, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 140.29M shares outstanding
Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices.
The firm primarily serves orthopedic and neurological surgeons both within the United States and globally.
Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extremities, and posterolateral spine.
Additionally, the line features OsteoFactor, containing diverse proteins and peptides that facilitate bone formation and remodeling, along with OsteoWrap and OsteoVive Plus, a cellular bone matrix enriched with growth factors. 2. Allograft Technologies: Under the 3Demin brand, Xtant Medical provides a range of allografts (human bone grafts) engineered to maximize both osteoconductivity and osteoinductive capabilities. This includes specialized sports allografts used for repairing anterior and posterior cruciate ligaments, ACL reconstruction, and meniscal repairs. They also offer milled spinal allografts, where cortical bone is precisely shaped to specific dimensions, as well as traditional allografts applicable across numerous medical disciplines such such as orthopedics, neurology, podiatry, oral/maxillofacial surgery, genitourinary, and plastic/reconstructive surgery. 3. Spinal Fixation and Fusion Systems: The company furnishes a variety of sophisticated spinal devices. These include the Certex spinal fixation system, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, the Xpress minimally invasive pedicle screw system, and Fortex Pedicle screw systems. Further systems encompass Calix, for use in cervical and thoracolumbar regions, the Axle-X interspinous fusion system, Irix-C for cervical integrated fusion, and the Irix-A Lumbar integrated fusion system.
The company underwent a name change in July 2015, transitioning from its former identity as Bacterin International Holdings, Inc. to Xtant Medical Holdings, Inc.
Leadership
Abhinav Jain
Director
John K. Bakewell
Director
Jonn R. Beeson
Director
Mark Schallenberger
Chief Operations Officer
Employees
151
Country
US
Sector
Healthcare
Website
xtantmedical.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Grant/Award | 215.5K | -- | Aug 15, 2026 | |
| Director | Grant/Award | 215.5K | -- | Aug 15, 2026 | |
| Director | Grant/Award | 215.5K | -- | Aug 15, 2026 | |
| President and CEO | Grant/Award | 550.0K | -- | Aug 15, 2026 | |
| President and CEO | Automatic Sell | 10.6K | $3.3K | Aug 15, 2026 | |
| CFO and Assistant Secretary | Grant/Award | 400.0K | -- | Aug 15, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Nantahala Capital Management, LLC | 68.4M | 48.8% | 13F |
Nantahala Capital Partners Limited Partnership · also on 13F· may incl. warrants· filed Aug 2025 | 16.4M | 11.7% | 13D |
Altium Capital Management, LP EIN 82-2066653 · filed Feb 2024 | 8.0M | 5.7% | 13G |
Vizirgianakis Stavros G. Director | 7.8M | 5.6% | FORM 4 |
LYTTON LAURENCE W · may incl. warrants· filed Feb 2026 | 7.7M | 5.5% | 13G |
AWM Investment Company, Inc. | 6.0M | 4.3% | 13F |
Browne Sean E President and CEO, Director | 3.1M | 2.2% | FORM 4 |
VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | 1.4% | 13F |
Neils Scott C CFO and Assistant Secretary | 1.2M | 0.9% | FORM 4 |
BAKEWELL JOHN K Director | 1.1M | 0.8% | FORM 4 |
Insiders
- Beeson Jonn R.Director
- Lipschultz TylerDirector
- BAKEWELL JOHN KDirector
- Browne Sean EPresident and CEO
- Neils Scott CCFO and Assistant Secretary
- Schallenberger Mark A.Chief Operating Officer
- Vizirgianakis Stavros G.Director
- JAIN ABHINAVDirector
- ORBIMED ADVISORS LLC10% Owner
Top institutional holders
based on 140.29M shares outstanding
30d Avg
125.40K
60d Avg
2.51M
90d Avg
1.72M